Medical Content Writer

November 8, 2025

Vimzim is mainly composed of the most important substance known as Elosulfase Alfa. It is used to treat a rare genetic disorder known as mucopolysaccharidosis IV A (also called MPS IVA or Morquio A syndrome). According to the global record, ~1 in 150,000–250,000 births are affected with MPS IVA.

Mode of action

MPS IVA is due to the absence of an enzyme known as N-acetylgalactosamine-6-sulfatase, which plays a role in breaking down substances in the body called glycosaminoglycans (GAGs), which eventually build up in the bones and organs, causing short bones, difficulty in moving and breathing, clouding of the eyes and hearing loss. N-acetylgalactosamine-6-sulfatase in Elosulfase Alfa is the active substance present in Vimzim, which breaks down glycosaminoglycans (GAGs) in the body and stops the cells from building up randomly, resulting in reduced symptoms in patients suffering from MPS IVA.

Indications

Vimzim is indicated in patients suffering from mucopolysaccharidosis IV A (also called MPS IVA or Morquio A syndrome)

Side Effects

The common symptoms in patients taking this medicine are headache, nausea, vomiting, abdominal pain, diarrhoea, dizziness, chills, difficulty in breathing and oropharyngeal pain.

Import guidance

Elosulfase Alfa availability in India is not permitted as of the present date, but we can import into India only by the legal procedure, since it is not registered with the Central Drugs Standard Control Organisation (CDSCO) for domestic distribution.

Steps to Import Elosulfase Alfa

Send the Elosulfase Alfa request for an order on the website: To begin with, we kindly ask either the patients or their supporters to send all the therapeutic requirements, like prescriptions and the medical history of the patient since diagnosed with MPS IVA.
Form submission: Please submit the document under the Form No.12A for the permission from the Central Drugs Standard Control Organisation (CDSCO) to import Vimzim (Elosulfase Alfa) as required. Make sure to send a genuine prescription from a Registered Medical Practitioner (RMD).
Reviewing medical documents: We review all the submitted medical documents to make the import process smooth and to deliver the medicine to you for your personal medical use.
Permission to import: We start our import process for medicines when the medical sanctioning of the patient is approved by the government authorities.
Authorised Sourcing of the product: Our sourcing team coordinates with the best international marketers and finalises at the most favourable price.
Order Execution: Lastly, we take responsibility for all the shipments till the medicine reaches you.

Read our detailed guide on how to Buy Elosulfase Alfa in India safely and legally.

Elosulfase Alfa Price in India

It is available in the brand name of BioMarin in the injection form as 5ml Vials. Since it is an enzyme replacement therapy, we set the Elosulfase alfa price in India according to the global standards. Also, its price keeps fluctuating depending on the weight and dosage of the patient, warehouses and government taxes.

Conclusion

If you are planning to buy Vimzim online in India or check Vimzim availability, 24/7QualityMeds can provide support throughout the entire import procedure. We are committed to extending assistance in helping patients to import Elosulfase Alfa and other prescription medicines legally by maintaining transparency through all the steps. Contact us today to buy Vimzim in India, because we get the right medication at the right time.

by Dr. Banisetti Sravya

November 7, 2025

Sacituzumab Govitecan is considered the main element in Trodelvy, which helps in treating adult patients with Triple-negative breast cancer. It is used to treat patients with advanced stages of Triple-negative breast cancer (TNBC). India estimates that 25-31% breast cancers are TNBC.

How does Trodelvy (Sacituzumab Govitecan) work?

Sacituzumab Govitecan is a combination of two active components.

Sacituzumab, which is a type of targeted therapy drug called a monoclonal antibody, and
SN-38, a chemotherapy drug.

Many breast cancer cells consist of a protein named ‘Trop-2’ on their surface. This protein transmits signals to breast cancer cells that promote progression. Sacituzumab is targeted to attach to Trop-2 and blocks it from transmitting the signals further. Now the SN-38 gets activated, which is aiming directly at breast cancer cells, eventually stopping cancer-causing cells from expanding. The impact of chemotherapy causes less harm to the healthy cells of your body by acting specifically on cancer cells. Patients can also explore our detailed guide on Trodelvy price, availability, and import access in India.

Indications:

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease (spreading to other parts of the body).
Unresectable locally advanced metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor (HER2)-negative (IHC0, IHC 1+ or IHC2+/ISH-breast cancer who received endocrine-based therapy (Hormone therapy) and at least two additional therapies in the metastatic setting.

Side effects:

The common side effects of Trodelvy are mentioned below:

Neutropenia (Low White blood cell count)
Severe Diarrhoea
Nausea
Vomiting
Hair loss
Allergic reactions
Fatigue
Light-headedness
Decreased appetite
Difficulty in breathing

Pricing and Availability:

The Sacituzumab Govitecan is not registered yet, as the Central Drug Standard Control Organisation (CDSCO) has not approved this medicine in India. So, the availability becomes limited, and patients can order only if it is prescribed by the doctor, after which we assist patients to buy Trodelvy in India through the legal way, right from the document verification to the final delivery of the product. The Sacituzumab Govitecan price in India may vary and depend on various factors like GST/local taxes, exchange rates, and changes in pricing policies of the company.

Safe Access:

Trodelvy is supplied in the form of one vial per box. Each single-dose vial consists of 180mg of Sacituzumab Govitecan (though some documentation shows 200mg fill as a manufacturing detail).

Steps to import process:

1) Request an order for Trodelvy : The patients or their family members can forward the prescription details and course of treatment. 2) Submission of a legal form (Form No.12) : We not only help in filing the Form No. 12A but also guide you in submitting it to the Drugs Controller General (India). Alongside this, a prescription from a Registered Medical Practitioner (RMP) is required. 3) Authentication of documents includes : Our team verifies the doctor’s prescription and all the required documents to ensure that the eligibility criteria for importing Trodelvy are according to legal guidelines. 4) Permission to import the medicine : We start the import process of the medicine as we get permission from the Drugs Controller General (India). 5) Authentic Product Sourcing : Our team connects with the authorised global suppliers and makes the best possible deal for the patient 6) Shipment and Delivery of the Medicine : We manage the logistics and coordinate with shipment procurement for safe and timely delivery of the medicine by all means.

Conclusion

If you are looking for any assistance to access sacituzumab govitecan in India? Connect with us at 24/7QualityMeds to get the sacituzumab govitecan price in India and also complete the process with ease according to legal ways and reliable sources.

by Dr. Banisetti Sravya

November 6, 2025

Truqap or capivasertib is a serine/threonine kinase inhibitor. It inhibits the enzymatic activity of serine/threonine kinase isoforms AKT 1, 2, and 3, which play a role in proliferation of cancer cells with mutations in PIK3CA, AKT1 or PTEN genes. Thus, it aids in reducing the growth of cancer cells. It is indicated, in combination with fulvestrant (anti-oestrogen medicine) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-mutations (as detected by an FDA-approved test) following progression on at least one endocrine-based regimen like aromatase inhibitor (to reduce estrogen levels) in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Common adverse reactions to treatment with capivasertib include diarrhea, cutaneous adverse reactions, increased random glucose or hyperglycemia, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting and stomatitis. Capivasertib may cause fetal harm. Hence, it is advised to avoid use in pregnancy. Confirm negative pregnancy status before starting treatment. Use of effective contraception during treatment and for 4 months after the last dose, is advised. Do not breastfeed during treatment due to potential for serious harm to infants. Not established as safe or effective for pediatric use. No efficacy differences in those ≥65 years, but higher rates of adverse reactions and treatment modifications. No dose changes needed for mild/moderate renal or hepatic impairment. Not studied in severe impairment. Monitor moderate hepatic cases closely.

Pricing and Availability

Capivasertib is not registered for commercial sale in India and is therefore unavailable through standard pharmacies or local distributors. As this is a prescription-only therapy, pricing details for capivasertib are provided upon request, following the submission of valid medical documents and a doctor’s prescription. For the latest pricing information and procurement assistance, patients or caregivers are encouraged to contact our team directly. The cost of capivasertib in India may vary depending on several factors, including supplier source, market conditions, regulatory requirements, and international availability. Additional elements such as shipping costs, documentation fees, origin country, and currency exchange rates may also influence the final price. Fluctuations in GST or local taxes, as well as adjustments in manufacturer pricing policies, can further affect total cost. We facilitate patient access to capivasertib in India under the Named Patient Supply (NPS) program, ensuring full legal and regulatory compliance. Our dedicated support team oversees the process from document verification to final delivery, ensuring safety and transparency at each stage.

Access Pathway

Since capivasertib is not commercially licensed in India, it can only be accessed through the Named Patient Import Program (NPIP). Using this pathway, we assist patients in obtaining unregistered medicines like capivasertib under the NPIP framework, ensuring the process follows all applicable import regulations.

Through this program, we provide guidance on the necessary steps, documentation, and regulatory requirements, helping patients access the treatment they need safely and efficiently. Our support ensures that the import process is smooth while remaining fully compliant with Indian laws.

Capivasertib or Truqap is available as 64 film coated tablets in one bottle, where each tablet contains 60mg or 200mg.

Import Process

1) Submit Your Request
The patient or caregiver starts by sending a request that includes basic treatment details and a valid prescription.

2) Fill Form 12A
Next, Form 12A is completed and submitted along with a prescription from a Registered Medical Practitioner (RMP).

3) Document Review
All medical and ID documents are checked to make sure the patient is eligible to import the medicine for personal use.

4) Get Approval
Once the Drugs Controller General of India (DCGI) approves the request, the import process can move forward as per the prescription.

5) Source the Medicine
Our team works with trusted international suppliers to get the required medicine at the best possible price, ensuring it is authentic and compliant.

6) Delivery to Your Address
After final clearance, customs and logistics are handled to ensure the medicine is safely and quickly delivered to the patient’s address in India.

Required Documentation

To import capivasertib in India, patients must provide:

Valid prescription from a doctor, mentioning the medicine name, dosage, duration of treatment, and diagnosis.
Recent medical history and supporting lab reports, preferably issued within the last three months.
Government-issued ID and proof of residence of the patient.
Import permit, if required.

Orders are finalized only upon receipt of all required documents and verification of medical eligibility. Once the import permit is approved, the licensed supplier arranges shipment of capivasertib from approved international sources such as the United States, Canada, Europe, or Australia. We ensure that every import is conducted safely, ethically, and in full regulatory compliance. Our organization provides nationwide delivery through verified suppliers, guaranteeing product authenticity and complete transparency in pricing and process. All prescriptions are reviewed and dispensed by registered pharmacists prior to delivery. If you are looking for more detailed information about this medication, its availability, or guidance with the import procedure, our team is here to support you every step of the way. For personalised assistance, pricing details, and expert help in sourcing the medicine safely and legally, please visit 247qualitymeds.com. We are committed to helping patients access the treatment they need with confidence and ease.

by Dr. Banisetti Sravya

November 5, 2025

Eculizumab is indicated for treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, anti-AchR antibody-positive generalised myasthenia gravis, and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder. It is administered as an intravenous infusion. It is a recombinant humanised monoclonal IgG antibody (IgG2/4𝛋) produced by murine myeloma cell culture. It specifically binds to C5, a complement protein, inhibiting cleavage to C5a and C5b, which ultimately leads to C5b-9. It inhibits the intravascular hemolysis caused by the terminal product in patients with complement-mediated thrombotic microangiopathy in patients with aHUS. The precise mechanism in gMG and NMOSD is unknown, but it is presumed to involve inhibition of antibody-induced complement deposition. There are certain risks in pregnant patients suffering from PNH and aHUS being administered Soliris. Published data does not report the presence of eculizumab in human milk, although maternal IgG may be present. No data on the effect on breastfed children or on milk production. Patients’ condition and potential effect on breastfed children need to be considered before deciding on treatment. Safety and effectiveness in pediatric patients have not been established – no apparent age-related differences in geriatric patients. Soliris or eculizumab is contraindicated in patients with unresolved Neisseria meningitidis infection and those who are not currently vaccinated against the same infection, unless the risk of delaying the eculizumab treatment outweighs the risks of developing meningococcal infection. Adverse reactions of the treatment include serious meningococcal infections, infusion reactions as well as any other systemic infection. Specific adverse reactions include headache, nasopharyngitis, back pain, nausea, diarrhoea, urinary and respiratory tract infections, peripheral edema, abdominal pain, musculoskeletal pain, among others.

Pricing and Availability

Eculizumab is not registered in India and, therefore, not easily available through local pharmacies or standard supply channels. As this is a prescription-only treatment, the price quotation for eculizumab is shared on request, after submission of valid medical documents. For the most current pricing and procurement details, patients or caregivers can contact us directly. The cost of eculizumab in India may differ depending on market trends, supplier access, and regulatory developments, since the medicine is not approved for commercial distribution in the country. The overall price also varies based on supplier, country of origin, shipping costs, and documentation requirements. Prices may further fluctuate due to GST/local taxes, currency exchange rates, and changes in manufacturer pricing policies. We assist patients to import eculizumab in India safely and lawfully, ensuring complete compliance with the Named Patient Supply (NPS) program. Our team supports patients through each step—from verifying documents to final delivery.

Access

As Eculizumab is not commercially approved in India, it can only be accessed through the Named Patient Import Program (NPIP). We support patients requiring medicines such as Eculizumab by helping procure them under the Named Patient Supply (NPS) route. Eculizumab injection is available as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton.

Import Process

Submit a request for your medicine Patients or caregivers can share their prescription and treatment details to initiate the request.
Apply through Form 12A An application in Form 12A must be submitted along with a valid prescription from a Registered Medical Practitioner (RMP).
Document verification All medical documents and prescriptions are verified to confirm eligibility for importing the medicine in small quantities for personal medical use.
Import permission Once approval is granted by the Drugs Controller General (India), the import procedure begins as per the prescription.
Sourcing the medicine Our sourcing team coordinates with authorized international suppliers to find the best available price in India, ensuring product authenticity before finalizing the purchase.
Medicine delivery After approval and confirmation, logistics are coordinated to ensure safe, compliant, and timely delivery to the patient’s address in India.

Required Documents

To enable the import of Eculizumab to India, patients must provide:

A valid prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the diagnosis.
Government-issued ID and proof of residence of the patient.
Import permit (if applicable).

The order is confirmed only after receiving a valid prescription and the required documents. Once the import permit is approved, the licensed supplier arranges shipment of eculizumab from approved international sources such as the USA, Canada, Europe, or Australia. Through this process, patients can import eculizumab into India safely and legally. We make the medicine available across major cities, sourcing only from genuine international suppliers to ensure quality and authenticity. We maintain complete transparency in pricing, and all prescriptions are reviewed by registered pharmacists before final dispatch. Any patients seeking comprehensive information about this medication, including availability and guidance, are encouraged to reach out. For detailed support or pricing assistance, please visit 247qualitymeds.com.

by Dr. Banisetti Sravya

November 4, 2025

Strensiq or asfotase alfa is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). HPP is caused by a deficiency in TNSALP enzyme activity, leading to elevations in several substrates, like inorganic pyrophosphate (PPi). TNSALP is a metalloenzyme that catalyzes the hydrolysis of phosphomonoesters with the release of inorganic phosphate and alcohol. Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix, which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with muscle weakness. Replacement of the TNSALP enzyme upon asfotase alfa treatment reduces the enzyme substrate levels. There are no available data on asfotase alfa use in pregnant women to inform a drug-associated risk, presence of asfotase alfa in human milk, the effects on the breastfed infant, or the effects on milk production. Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for asfotase alfa and any potential adverse effects on the breastfed infant from asfotase alfa or from the underlying maternal condition. Safety and effectiveness of asfotase alfa for the treatment of perinatal/infantile- and juvenile-onset HPP have been established in pediatric patients. There is no information available to determine whether geriatric patients differ in terms of adverse reactions and response, as compared to younger patients. Asfotase alfa is for subcutaneous injection only. The following are the most adverse reactions reported in patients undergoing treatment (incidence rates being gretaer than 10%) with asfotase alfa: hypersensitivity reactions, lipodystrophy, ectopic calcifications, and possible immune-mediated clinical effects

Pricing and Availability

Asfotase alfa is not currently registered in India and is therefore not available through regular pharmacies or standard distribution channels. As this is a prescription-only medication, a price quotation for asfotase alfa is shared only after reviewing valid medical documents and a doctor’s prescription. For the most up-to-date pricing and supply details, patients may contact our support team. The price of asfotase alfa in India may differ based on factors such as market demand, supplier access, import regulations, and availability from international manufacturers. The total cost may also depend on shipping charges, origin country, documentation fees, and currency exchange rates. Pricing may be affected by local taxes (GST) and any revisions in company or distributor pricing policies. We assist patients in India with the safe and lawful access through import asfotase alfa through the Named Patient Supply (NPS) program, ensuring compliance with all import regulations. Our services include document verification, import coordination, and doorstep delivery of the medicine.

Patient Access

Since asfotase alfa is not approved for commercial sale in India, it can be obtained only through the Named Patient Import Program (NPIP). We help patients obtain unregistered medicines under the NPS route, maintaining full adherence to applicable legal and regulatory standards. Strensiq or asfotase alfa is available as injection: 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or 80 mg/0.8 mL solution in single-dose vials with each carton containing 1 or 12 vials.

Import Procedure

Medicine Request Submission: Patients or caregivers can begin by submitting a request, along with their doctor’s prescription and treatment information.
Filing Form 12A: A completed Form 12A and a valid prescription from a Registered Medical Practitioner (RMP) must be submitted.
Verification Process: All documents are carefully reviewed to confirm the patient’s eligibility to import the medicine for personal medical use.
Regulatory Approval: Once approval is received from the Drugs Controller General (India), the import procedure is initiated in accordance with the approved prescription.
Medicine Procurement: Our procurement specialists connect with licensed international suppliers to source the medicine at the best possible rate while ensuring authenticity and quality.
Product Delivery: Following approval and shipment, logistics are handled to ensure timely, safe, and compliant delivery of the medicine to the patient’s address in India.

Documents Required

To import asfotase alfa into India, patients must provide the following:

A valid prescription indicating the medicine name, dosage, duration, and diagnosis.
Recent medical history and diagnostic reports (preferably from the last three months).
Government-issued ID proof and proof of residence.
Import permit (if required).

Orders are confirmed only after the submission and verification of all necessary documents. Once the import authorization is granted, shipment of asfotase alfa is arranged by a licensed global supplier typically from the USA, Canada, Europe, or Australia. This process ensures that patients in India can legally and securely access and buy asfotase alfa in India. We coordinate with reliable international sources, maintain pricing transparency, and ensure all deliveries are pharmacist-verified and fully compliant with import regulations. For the best pricing, authentic sourcing, and priority assistance, connect with 247QualityMeds.com today. Our team ensures a safe and easy buying process.

by Dr. Banisetti Sravya

November 3, 2025

Mirvetuximab soravtansine-gynx for the treatment of adult patients with FRα–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test. Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC) where the monoclonal antibody is a chimeric IgG1 that targets folate receptor alpha (FRα). Th antibody is linked to a small molecule, DM4 (also known as soravtansine or ravtansine), a microtubule inhibitor by a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death, and diffuse to nearby cells causing further cell death. FRα is a receptor that is overexpressen on the surface epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and non-small-cell lung cancers. The most common adverse reactions include vision impairment, pneumonitis, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased neutrophils, and decreased hemoglobin. The cytotoxic and gentoxic component DM4 can be toxic to actively dividing cells, suggesting its potential to cause embryotoxicity and teratogenicity. Advise patients of potential risk to fetus. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 month after the last dose. Advise females to use effective contraception during treatment and for 7 months after the last dose. Safety and effectiveness of mirvetuximab have not been established in pediatric patients. No clinically meaningful differences in efficacy or safety were observed in geriatric patients compared to younger patients. No dosage adjustment of mirvetuximab is recommended for patients with mild to moderate renal or mild hepatic impairment. The effect of severe renal impairment or end-stage renal disease on mirvetuximab is unknown. Avoid use of mirvetuximab in patients with moderate or severe hepatic impairment.

Pricing and Availability

Mirvetuximab Soravtansine (Elahere) is not registered in India and, therefore, not easily available through local pharmacies or standard supply channels. As this is a prescription-only treatment, the price quotation for mirvetuximab is shared on request, after submission of valid medical documents. For the most current pricing and procurement details, patients or caregivers can contact us directly. The cost of mirvetuximab in India may differ depending on market trends, supplier access, and regulatory developments, since the medicine is not approved for commercial distribution in the country. The overall price also varies based on supplier, country of origin, shipping costs, and documentation requirements. Prices may further fluctuate due to GST/local taxes, currency exchange rates, and changes in manufacturer pricing policies. We assist patients in importing mirvetuximab in India safely and lawfully, ensuring complete compliance with the Named Patient Supply (NPS) program. Our team supports patients through each step-from verifying documents to final delivery.

Access

As mirvetuximab is not commercially approved in India, it can only be accessed through the Named Patient Import Program (NPIP). We support patients requiring medicines by helping procure them under the Named Patient Supply (NPS) route. Each mirvetuximab soravtansine-gynx injection carton contains one single-dose vial containing 100 mg of mirvetuximab soravtansine-gynx in 20 mL (5 mg/mL) of clear to slightly opalescent, colorless sterile solution.

Import Process

Submit a request for your medicine Patients or caregivers can share their prescription and treatment details to initiate the request.
Apply through Form 12A An application in Form 12A must be submitted along with a valid prescription from a Registered Medical Practitioner (RMP).
Document verification All medical documents and prescriptions are verified to confirm eligibility for importing the medicine in small quantities for personal medical use.
Import permission Once approval is granted by the Drugs Controller General (India), the import procedure begins as per the prescription.
Sourcing the medicine Our sourcing team coordinates with authorized international suppliers to find the best available price of mirvetuximab soravtansine in India, ensuring product authenticity before finalizing the purchase.
Medicine delivery After approval and confirmation, logistics are coordinated to ensure safe, compliant, and timely delivery to the patient’s address in India.

Required Documents

To enable the import of mirvetuximab to India, patients must provide:

A valid prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the diagnosis.
Government-issued ID and proof of residence of the patient.
Import permit (if applicable).

The order is confirmed only after receiving a valid prescription and the required documents. Once the import permit is approved, the licensed supplier arranges shipment of mirvetuximab from approved international sources such as the USA, Canada, Europe, or Australia. Through this process, patients can import mirvetuximab into India safely and legally. We make the medicine available across major cities, sourcing only from genuine international suppliers to ensure quality and authenticity. We maintain complete transparency in pricing, and all prescriptions are reviewed by registered pharmacists before final dispatch. For pricing details or to request assistance in accessing mirvetuximab, visit 24/7QualityMeds.com.

by Dr. Banisetti Sravya

November 1, 2025

Foscavir is the brand name for foscarnet sodium. Foscarnet exerts its antiviral activity by a selectively inhibiting the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. It does not require activation by thymidine kinase or other kinases. Foscarnet is indicated for the treatment of:

CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). The combination of foscarnet and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. Safety and efficacy of foscavir have not been established for treatment of other CMV infections (e.g., pneumonitis, gastroenteritis); congenital or neonatal CMV disease; or nonimmunocompromised individuals.
Acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. Safety and efficacy of foscarnet have not been established for treatment of other HSV infections (e.g., retinitis, encephalitis); congenital or neonatal HSV disease; or HSV in nonimmunocompromised individuals.

Adverse reactions of this medicine primarily include renal impairment, mineral and electrolyte abnormalities, seizures, hypersensitivity, QT prolongation. Insufficient well-controlled studies of foscavir is not done in pregnant women. There is potential for serious adverse events in nursing infants, and hence a decision should be made considering the importance of the drug to the mother. The safety and effectiveness of foscavir in pediatric patients have not been established. Since deposition in human bone has also been shown to occur, it is likely that it does so to a greater degree in developing bone in pediatric patients. No studies regarding efficacy or safety of foscavir in geriatric patients, however consistent patterns in adverse reactions seen across all age groups. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are at higher chance of having impaired renal function, care should be taken in dose selection, with monitoring of renal function. Read our detailed overview of Foscavir indications, safety profile, and ordering options in India.

Pricing and availability:

Foscarnet is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for Foscavir is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of foscarnet in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Learn more about Foscarnet availability, import procedures, and legal access options in India. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients to buy foscarnet in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As foscarnet is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like foscarnet in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Foscavir or foscarnet (foscarnet sodium) injection, 24 mg/mL, for intravenous infusion, is supplied in 250 mL glass bottles containing 6000 mg foscarnet sodium (24 mg/mL) as 250 mL bottles, or in cases of 10.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best foscarnet price in India, thus making it convenient to easily import foscarnet in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Foscavir from the USA, Canada, Europe, or Australia etc.

With these steps, patients can import Foscarnet in India safely and legally. We ensure availability across major Indian cities and source only from verified international suppliers to maintain product authenticity and quality. Pricing is fully transparent, and all prescriptions are verified by registered pharmacists before delivery. For assistance with pricing, documentation, or procurement, patients may contact 24/7Qualitymeds for reliable support and seamless access.

by Dr. Banisetti Sravya

October 30, 2025

Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) witj the KRAS-G12C mutation in adults who have received at least one prior systemic therapy. It is additionally approved in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluorouracil-, oxaliplatin– and irinotecan-based chemotherapy. The usual pathway consists of GTP binding to KRAS, aloowing downstream signalling through MAP kinase pathway. GTP is hydrolyzed to GDP, and KRAS is inactivated. KRAS G12C mutations impair hydrolysis of GTP, leaving it in the active form. Sotorasib, being a KRASG12C inhibitor, binds to the cysteine residue in KRAS G12C mutations, holding the protein in its inactive form. The cysteine residue that sotorasib targets is not present in the wild type KRAS, which prevents off-target effects. This mutation is present in 13% of non-small cell lung cancer, 3% of colorectal and appendix cancer, and 1-3% of solid tumors. This enables blocking and KRAS signaling, inhibited cell growth, and promoted apoptosis specifically in KRAS G12C tumor cell lines. This product has inhibited KRASG12C in vitro and in vivo with minimal detectable off-target activity. In mouse tumor xenograft models, sotorasib treatment led to tumor regressions and prolonged survival, and was associated with anti-tumor immunity in KRAS G12C models. There are no available data on Sotorasib use in pregnant women. Because of the potential for serious adverse reactions in breastfed children, women are advised not to breastfeed during treatment with Lumakras and for 1 week after the final dose. The safety and effectiveness of this product have not been established in pediatric patients. No overall differences in safety or effectiveness were observed between older patients and younger patients. No dosage modification is recommended in patients with mild to moderate hepatic impairment (Child Pugh A or B). The effect of severe hepatic impairment (Child-Pugh C) on the safety of LUMAKRAS is unknown. Monitor for sotorasib adverse reactions in patients with hepatic impairment more frequently since these patients may be at increased risk for adverse reactions including hepatotoxici

Pricing and availability:

Sotorasib is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for sotorasib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of sotorasib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy sotorasib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As sotorasib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like sotorasib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Sotorasib or Lumakras is available as 320 mg tablets in carton containing one bottle of 90 tablets with child-resistant closure and as 120 mg tablets in carton containing two bottles of 120 tablets or one bottle of 240 tablets with child-resistant closure,

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best sotorasib price in India, thus making it convenient to easily access Lumakras in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Lumakras from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import sotorasib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients. If you are exploring reliable options to buy Sotorasib (Lumakras) in India, expert assistance is available. For accurate pricing, availability updates, and end-to-end support with the import process, you may reach out to 24/7QualityMeds. Their team helps ensure compliant sourcing and smooth delivery so patients can access this essential therapy with confidence.

by Dr. Banisetti Sravya

October 29, 2025

Mitotane is indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane or Lysodren is an adrenal cytotoxic agent which can cause adrenal inhibition, apparently without cellular destruction. The exact biochemical mechanism of action is unknown. Available data suggest that the drug modifies the peripheral metabolism of steroids as well as suppresses the adrenal cortex. It ultimately leads to reduced production of adrenal corticosteroids and aids in accumulation of free cholesterol toxic to adrenal cells. Learn more about Mitotane import guidelines and access options in India. Adverse reactions include gastrointestinal disturbances like anorexia, nausea or vomiting, and diarrhea; central nervous system side effects, primarily depression as manifested by lethargy and somnolence, dizziness or vertigo; skin toxicity, et cetera. Infrequently occurring side effects involve the eye, the genitourinary, cardiovascular system; and generalized aching, hyperpyrexia, and lowered protein bound iodine. Mitotane or Lysodren is usually present in breast- milk. Hence, women are advised not to breastfeed during treatment. Safety and effectiveness in pediatric and geriatric patients has not been established sufficiently. In few clinical studies performed with geriatric patients, no significant differences in adverse reaction occurrence. However, dose adjustments are required in consideration with the co-occurence of hepatic, renal, cardiac impairment as well as any other drug or treatment being used.

Pricing and availability:

Mitotane is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for mitotane is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of mitotane in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients Buy Mitotane (Lysodren) in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As mitotane is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Mitotane or Lysodren is available as 500 mg tablets, 100 in each bottle. Read why regular Mitotane blood level monitoring is essential during treatment.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best mitotane price in India, thus making it convenient to easily import mitotane in India and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Lysodren from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import Mitotane in India safely and legally. We source only from verified international suppliers to ensure authenticity and make the medicine available across major Indian cities. Every order is handled with 100% transparency, and Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

For guidance on pricing, availability, and compliant import support for Mitotane, you can connect with 24/7QualityMeds for seamless assistance.

by Dr. Banisetti Sravya

October 28, 2025

Braftovi or encorafenib is a prescription medication used to treat certain cancers that have spread (metastasized), cannot be removed with surgery, and have specific mutations in the BRAF gene. It is used in to treat (a) Melanoma and Non-Small Cell Lung Cancer (NSCLC): In combination with Mektovi (binimetinib), encorafenib is used to treat adults with melanoma or NSCLC that has a BRAF mutation. (b) Colorectal Cancer (CRC): In combination with cetuximab and mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) to treat colorectal cancer. Read more about Braftovi uses, indications, and side effects in India. The approval for this combination was based on response of the tumour and its duration. Ongoing studies are evaluating the clinical benefit of this regimen. Encorafenib may also be used in combination with cetuximab alone for adults with colorectal cancer who have previously received treatment. Encorafenib is advised against for the treatment of people whose melanoma, colorectal cancer, or NSCLC has wild-type BRAF (no BRAF mutation), due to insufficient studies. Your healthcare provider will perform a test to confirm if encorafenib or the combination with binimetinib is appropriate for your condition. Encorafenib is a BRAF kinase inhibitor targeting mutated BRAF – BRAF V600E, wild-type BRAF, and CRAF, inhibiting tumor growth via the suppression of RAF/MEK/ERK pathway. It also binds other kinases at clinically relevant levels. In combination with binimetinib or cetuximab, it showed better anti-tumor effects and delayed resistance in BRAF-mutant models. Resistance in BRAF-mutant CRC due to EGFR activation can be overcome with EGFR-targeted combination therapy. New primary malignancies, hemorrhage, uveitis and QT prolongation are the common side effects of encorafenib treatment. Breastfeeding is not recommended during treatment and for 2 weeks after. Encorafenib may impact and impair male fertility and reduce any effectiveness of hormonal contraceptives. Therefore, non-hormonal contraception is advised. Effective contraception used during and for 2 weeks after therapy. In clinical trials, no significant effect of the product’s safety or effectiveness were seen in elderly patients. However, it is not approved for pediatric use. No dose adjustment is needed for mild to moderate renal or hepatic impairment, and use in severe impairment lacks dosing recommendations.

Pricing and availability:

Encorafenib (Braftovi) is a targeted therapy designed for adults with melanoma, NSCLC, and colorectal cancer with a BRAF mutation that have spread or cannot be surgically removed. It aids in improving tumor response and the duration of benefit. When used in combination with binimetinib or cetuximab-based regimens, it offers a powerful, personalized treatment. It is not suitable for cancers without the BRAF mutation. However, encorafenib is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for encorafenib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of encorafenib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Explore our detailed guide on Encorafenib pricing, import steps, and patient access in India. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy encorafenib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As encorafenib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Braftovi or encorafenib is supplied as 75 mg capsules available in cartons containing two bottles of 90 capsules each and cartons containing two bottles of 60 capsules each.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best encorafenib price in India, thus making it convenient to easily import encorafenib in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Braftovi from the USA, Canada, Europe, or Australia, etc. With these steps, patients can buy encorafenib in India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

Accessing Encorafenib (Braftovi) in India can be made seamless and compliant through the Named Patient Supply (NPS) Program. With proper guidance, patients can obtain this essential therapy safely and legally under the supervision of qualified healthcare professionals.

At 24/7 QualityMeds, we assist patients and caregivers through every stage—from documentation and regulatory approvals to sourcing from verified international suppliers. Our focus is on ensuring genuine medicines, transparent pricing, and reliable delivery across India. For the most updated details on Encorafenib pricing, availability, and import assistance in India, please contact our expert support team.

by Dr. Banisetti Sravya

October 25, 2025

Tukysa is a HER2-directed tyrosine kinase inhibitor approved in combination therapy that has demonstrated a significant overall survival benefit in patients with HER2-positive metastatic breast cancer—including those with brain metastases. Its ability to cross the blood-brain barrier and maintain efficacy makes it a critical advancement in treatment of HER2+ disease. Its favorable tolerability profile, and ability to be used post multiple HER2-targeted therapies make it a valuable option in the treatment landscape for HER2-positive metastatic breast cancer. This product manufactured by Seagen (Seattle Genetics) is a HER2-directed kinase inhibitor, meaning it blocks HER2 and HER3 phosphorylation in vitro, inhibiting downstream MAPK and AKT signaling, and reducing cell proliferation. It has shown anti-tumor activity in HER2-expressing cells. In vivo, tucatinib inhibited HER2-positive tumor growth. When combined with trastuzumab, tucatinib demonstrated enhanced anti-tumor effects in both in vitro and in vivo models compared to either agent alone. Recommended dosage is 300 mg, orally, twice daily with or without food; and for patients with severe hepatic impairment is 200 mg orally twice daily. Some of the clinically significant adverse reactions include diarrhea, embryo fetal toxicity and hepatotoxicity.

Pricing and availability:

Tucatinib (Tukysa) is prescribed for patients with HER2- positive metastatic breast cancer. However, tucatinib is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for tucatinib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of tucatinib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy tucatinib in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery. Explore our complete guide on Tucatinib (Tukysa) cost, import process, and access options in India.

Access:

As tucatinib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like tucatinib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Tukysa or tucatinib is supplied as 50 mg or 150 mg tablets with 60 counts in each of 75 cc bottles or 150 mg tablets as 120 counts in each of 150 cc bottles.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, thus making it convenient to easily import tucatinib in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Tukysa from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import tucatinib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

by Dr. Banisetti Sravya

October 17, 2025

Kineret, also known by its generic name Anakinra, is a biologic prescription medicine that belongs to the class of interleukin-1 receptor antagonists (IL-1Ra), produced by recombinant DNA technology. It works by blocking the activity of interleukin-1 (IL-1), a protein involved in inflammation. By reducing IL-1 activity, it helps control symptoms and progression of several rare and severe inflammatory diseases.

Kineret is approved for treating:

Rheumatoid Arthritis (RA) in adults who have not responded to one or more other treatments.
Neonatal-Onset Multisystem Inflammatory Disease (NOMID): A rare form of Cryopyrin-Associated Periodic Syndromes (CAPS).
Deficiency of Interleukin-1 Receptor Antagonist (DIRA): A life-threatening genetic condition

Adverse reactions can include infections in upper respiraotory tract, injection site reaction, worsening of rheumatoid arthritis,, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain in RA patients; injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis in NOMID patients; upper respiratory tract infections, rash, pyrexia, influenza like illness, and gastroenteritis in DIRA patients. Higher risk of adverse reactions and their severity in geriatric patients and those with renal impairment. Refer label for detailed drug information. Anakinra (Kineret) is a vital biologic therapy for patients with Rheumatoid Arthritis, NOMID, and DIRA, offering significant improvements in health outcomes and, in some cases, survival. While the Kineret price in India can vary, legal import channels ensure transparency and access to genuine medicine.

Pricing and availability:

Anakinra is prescribed for patients requiring treatment of rheumatoid arthritis, NOMID and DIRA. However, ankainnra is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for anakinra is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of anakinra (Kineret) in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Read more about Anakinra pricing, import guidelines, and access options in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy anakinra India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As Anakinra is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients to products like Kineret in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Anakinra or Kineret is supplied in 100 mg/0.67 mL prefilled syringes (packs of 28 injections),

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, confirm easy import of anakinra in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Kineret from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import anakinra in India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients. Learn more about Kineret (Anakinra) uses, dosage, and where to buy in India

Newer Posts

Older Posts